Dalteparin

Revision as of 23:26, 12 November 2016 by ClaireLewis (talk | contribs) (→‎See Also)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

Adult Dosing

  • PE/DVT treatment: 200 units/kg SC q24h, max 18,000 units
  • VTE prophylaxis: 2500-5000 units subQ daily

Pediatric Dosing

Safety/efficacy not established

  • PE/DVT treatment: 129 +/- 43 units/kg subQ daily, adjust dose to goal anti-Xa activity 0.5-1 unit/mL 4-6 hours after injection
  • VTE prophylaxis: 92 +/- 52 units/kg subQ daily

Special Populations

Contraindications

  • Allergy to class/drug
  • Active major bleeding
  • History of heparin-induced thrombocytopenia
  • Use for VTE prophylaxis or to treat NSTEMI/UA in patients undergoing neuraxial or epidural anesthesia

Adverse Reactions

Serious

  • Major bleeding: epidural hematoma, spinal hematoma, intracranial hemorrhage, subdural hemorrhage, hemorrhagic stroke, intrauterine hemorrhage
  • Thrombocytopenia
  • Paralysis

Common

  • Injection site hematoma, pain, irritation

Pharmacology

  • Half-life: 3-5h
  • Metabolism:
  • Excretion: Renal

Mechanism of Action

  • Low-molecular weight heparin: binds antithrombin and inhibits coagulation Factor Xa and thrombin

Comments

See Also

References

Authors: